Separately, Rakovina Therapeutics expects to receive the first synthesized drug candidates from its second AI-driven drug discovery program targeting ATR.

Tech giant OpenAI has unveiled a pay-for-access tool called ‘deep research’, which synthesizes information from dozens or ...